New combo treatment aims to control aggressive throat cancer
NCT ID NCT07290621
Summary
This study is testing a new treatment approach for HPV16-positive throat cancer that has not been treated before. Patients first receive an immunotherapy drug (toripalimab) combined with chemotherapy to shrink the tumor. Based on how well the tumor responds, patients then undergo either robotic surgery or a tailored course of radiation/chemotherapy, aiming to control the cancer while potentially reducing side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Chicago Medicine Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.